-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
KeyCorp Analysts Lower Earnings Estimates for AngioDynamics, Inc. (NASDAQ:ANGO)
KeyCorp Analysts Lower Earnings Estimates for AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) – Research analysts at KeyCorp cut their FY2024 earnings per share estimates for AngioDynamics in a research note issued on Thursday, January 5th. KeyCorp analyst M. Mishan now anticipates that the medical instruments supplier will post earnings per share of $0.12 for the year, down from their previous estimate of $0.18. The consensus estimate for AngioDynamics' current full-year earnings is $0.01 per share. KeyCorp also issued estimates for AngioDynamics' FY2025 earnings at $0.27 EPS.
Get AngioDynamics alerts:A number of other equities research analysts also recently commented on the company. StockNews.com began coverage on AngioDynamics in a research report on Wednesday, October 12th. They issued a "hold" rating on the stock. Raymond James reduced their price target on shares of AngioDynamics from $25.00 to $22.00 and set a "strong-buy" rating for the company in a research report on Friday.
AngioDynamics Price Performance
Shares of ANGO stock opened at $15.17 on Monday. The firm's 50-day moving average is $13.41 and its two-hundred day moving average is $17.87. AngioDynamics has a 12 month low of $11.71 and a 12 month high of $24.87. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.16 and a quick ratio of 1.41. The company has a market capitalization of $593.27 million, a PE ratio of -18.28 and a beta of 0.66.AngioDynamics (NASDAQ:ANGO – Get Rating) last released its earnings results on Thursday, October 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.04). AngioDynamics had a negative net margin of 9.98% and a negative return on equity of 0.14%. The firm had revenue of $81.50 million during the quarter, compared to analysts' expectations of $83.43 million. During the same quarter last year, the business earned ($0.02) EPS. The business's revenue was up 5.8% compared to the same quarter last year.
Hedge Funds Weigh In On AngioDynamics
Several hedge funds and other institutional investors have recently made changes to their positions in ANGO. Texas Permanent School Fund raised its position in shares of AngioDynamics by 2.1% in the 2nd quarter. Texas Permanent School Fund now owns 28,029 shares of the medical instruments supplier's stock valued at $542,000 after purchasing an additional 580 shares in the last quarter. US Bancorp DE boosted its holdings in shares of AngioDynamics by 36.2% in the 2nd quarter. US Bancorp DE now owns 2,562 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 681 shares during the period. Legal & General Group Plc lifted its stake in AngioDynamics by 0.9% in the second quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier's stock valued at $1,802,000 after buying an additional 851 shares during the last quarter. Brinker Capital Investments LLC grew its position in AngioDynamics by 2.3% in the 1st quarter. Brinker Capital Investments LLC now owns 41,539 shares of the medical instruments supplier's stock worth $895,000 after purchasing an additional 929 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its holdings in AngioDynamics by 16.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 6,513 shares of the medical instruments supplier's stock worth $126,000 after buying an additional 934 shares in the last quarter. Institutional investors and hedge funds own 94.94% of the company's stock.
About AngioDynamics
(Get Rating)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
Recommended Stories
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
AngioDynamic,Inc.(納斯達克代碼:Ango-Get Rating)-KeyCorp的研究分析師在1月5日星期四發佈的一份研究報告中下調了對AngioDynamic 2024財年每股收益的預期。KeyCorp分析師M·米山現在預計,這家醫療器械供應商今年的每股收益將為0.12美元,低於此前預期的0.18美元。對AngioDynamic目前全年收益的普遍估計是每股0.01美元。KeyCorp還發布了對AngioDynamic 2025財年每股收益的估計為0.27美元。
到達血管動力學警報:其他一些股票研究分析師最近也對該公司發表了評論。StockNews.com在10月12日星期三的一份研究報告中開始報道AngioDynamic。他們對該股的評級為“持有”。Raymond James將AngioDynamic的股票目標價從25.00美元下調至22.00美元,並在週五的一份研究報告中為該公司設定了“強力買入”評級。
血管動力學性價比
週一,Ango的股票開盤報15.17美元。該公司的50日移動均線切入位在13.41美元,200日移動均線切入位在17.87美元。AngioDynamic的12個月低點為11.71美元,12個月高位為24.87美元。該公司的債務權益比為0.12,流動比率為2.16,速動比率為1.41。該公司市值為5.9327億美元,本益比為-18.28,貝塔係數為0.66。AngioDynamic(納斯達克:Ango-Get Rating)最近一次公佈財報是在10月6日(星期四)。這家醫療器械供應商公佈了本季度每股收益(0.06美元),低於普遍預期的(0.02美元)和(0.04美元)。AngioDynamic的淨利潤率為負9.98%,股本回報率為負0.14%。該公司本季度營收為8,150萬美元,高於分析師預期的8,343萬美元。去年同期,該業務實現每股收益(0.02美元)。與去年同期相比,該業務的收入增長了5.8%。
對沖基金參與AngioDynamic
幾家對沖基金和其他機構投資者最近對他們在Ango的頭寸進行了調整。德克薩斯永久學校基金在第二季度將其在AngioDynamic股票的頭寸提高了2.1%。德克薩斯永久學校基金現在擁有這家醫療器械供應商的28,029股股票,價值542,000美元,上個季度又購買了580股。US Bancorp DE在第二季度增持了36.2%的AngioDynamic股票。在此期間,US Bancorp DE又購買了681股,現在擁有2562股這家醫療器械供應商的股票,價值5萬美元。Legal&General Group Plc在第二季度將其在AngioDynamic的持股比例提高了0.9%。Legal&General Group Plc現在擁有這家醫療器械供應商93,102股股票,價值1,802,000美元,上個季度又購買了851股。Brinker Capital Investments LLC在第一季度將其在AngioDynamic的頭寸增加了2.3%。Brinker Capital Investments LLC現在擁有這家醫療器械供應商41,539股股票,價值895,000美元,上個季度又購買了929股。最後,美國互惠資本管理有限責任公司在第二季度增持了16.7%的AngioDynamic股份。美國互惠資本管理公司現在持有這家醫療器械供應商6,513股股票,價值12.6萬美元,上個季度又購買了934股。機構投資者和對沖基金持有該公司94.94%的股票。
關於血管動力學
(獲取評級)
AngioDynamic公司設計、製造和銷售各種醫療、手術和診斷設備,由專業保健提供商用於治療外周血管疾病和血管通路,並用於美國和國際上的腫瘤學和外科環境。
推薦故事
- 免費獲取StockNews.com關於血管動力學的研究報告(Ango)
- 理想汽車會成為2023年最不招人恨的中國電動汽車股嗎?
- 以下是Snap股票在2023年翻一番的原因
- 哪種流媒體服務股票是2023年最好的?
- MarketBeat:回顧中的一週01/02-01/06
- 為什麼CrowdStrike的股價舉步維艱?
接受《血管動力學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對AngioDynamic和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧